4 Stocks Dragging The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 91 points (0.6%) at 15,561 as of Thursday, July 18, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,136 issues advancing vs. 784 declining with 110 unchanged.

The Drugs industry currently sits up 5.9% versus the S&P 500, which is up 0.5%. On the negative front, top decliners within the industry include Biogen Idec ( BIIB), down 0.9%, and Bristol-Myers Squibb Company ( BMY), down 0.6%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Novartis ( NVS) is one of the companies pushing the Drugs industry lower today. As of noon trading, Novartis is down $0.38 (-0.5%) to $72.50 on average volume. Thus far, 1.0 million shares of Novartis exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $72.21-$72.85 after having opened the day at $72.53 as compared to the previous trading day's close of $72.88.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $180.5 billion and is part of the health care sector. Shares are up 15.1% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Novartis a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, reasonable valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novartis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Novartis CEO Joe Jimenez to Step Down in 2018

FDA Greenlights Novartis' Gene Therapy for Leukemia

Novartis' CAR-T Gene Therapy Receives FDA Approval

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)